SB-649868 is primarily investigated for its potential therapeutic applications in the treatment of sleep disorders, particularly insomnia. It functions as an orexin receptor antagonist, targeting the orexin system, which plays a crucial role in regulating wakefulness and sleep. By blocking orexin receptors, SB-649868 promotes sleep onset and maintenance, offering a promising alternative to traditional sedative-hypnotics. Its mechanism of action is believed to provide a more natural sleep pattern with reduced side effects, such as dependency or grogginess. Clinical studies have explored its efficacy in improving sleep quality and duration, making it a candidate for addressing chronic insomnia and other sleep-related conditions. Research continues to evaluate its long-term safety and effectiveness in diverse patient populations.